Literature DB >> 27566675

APOE Variants E2, E3, and E4 Can Be Miscalled By Classical PCR-RFLP When The Christchurch Variant Is Also Present.

Beatriz Candás-Estébanez1, Ariadna Padró-Miquel1, Cristina Ruiz-Iruela1, Emili Corbella-Inglés2, Xavier Pintó-Sala2, Pedro Alía-Ramos1.   

Abstract

BACKGROUND: The APOE Christchurch (APOECh) is a rare variant (c.543C>A) in codon 154. It was first described in an E2 patient with type III dyslipidemia, and thus initially called E2Ch. Its prevalence and the lipid profile of carriers remain unclear.
METHODS: E2, E3, and E4 screening for the APOE gene was performed by PCR-RFLP. The rare APOECh variant was firstly found after detecting an unexpected 109 base-pair band in the high-resolution agarose gel electrophoresis leading to a genotype misinterpretation: the presence of APOECh alters the restriction-bands pattern. To confirm the Ch variant, a second PCR-RFLP method was specifically designed to detect this variant and Sanger sequencing was also performed for all positive samples.
RESULTS: We identified 12 unrelated subjects for the APOECh among a cohort of 2,560 patients: nine E3/E3Ch, two E3Ch/E4, and one E2/E3Ch or E2Ch/E3. The frequency of the variant is 0.4% in our study population, which represents the highest percentage published so far. If there is a 109 bp band, it is easy to recognize the presence of the variant. However, in APOE routine genotyping, an E4Ch allele is indistinguishable from a standard E3. Therefore, E4Ch alleles might be underrepresented in the results.
CONCLUSION: We recommend APOE exon 4 sequencing to unequivocally detect the common three variants E2, E3, and E4 and the rare variants as well, to find out the real role they play in atherosclerosis and to estimate its real frequency which is nowadays unclear, in part by the small number of cases identified.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  APOE variants; Chirstchurch variant

Mesh:

Substances:

Year:  2016        PMID: 27566675      PMCID: PMC6817017          DOI: 10.1002/jcla.22040

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  12 in total

1.  Apolipoprotein E4 stimulates sulfation of glycosaminoglycans in neural cells.

Authors:  P Bonay; J Avila
Journal:  Biochim Biophys Acta       Date:  2001-03-26

2.  Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI.

Authors:  J E Hixson; D T Vernier
Journal:  J Lipid Res       Date:  1990-03       Impact factor: 5.922

3.  Incomplete dominance of type III hyperlipoproteinemia is associated with the rare apolipoprotein E2 (Arg136-->Ser) variant in multigenerational pedigree studies.

Authors:  M Pocovi; A Cenarro; F Civeira; R H Myers; E Casao; M Esteban; J M Ordovas
Journal:  Atherosclerosis       Date:  1996-04-26       Impact factor: 5.162

4.  Apolipoprotein E2-Christchurch (136 Arg----Ser). New variant of human apolipoprotein E in a patient with type III hyperlipoproteinemia.

Authors:  M R Wardell; S O Brennan; E D Janus; R Fraser; R W Carrell
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

5.  Rare variant of apolipoprotein E (Arg136 -->Ser) in two normolipidemic individuals.

Authors:  J A Hubácek; V Adámková; Z Skodová
Journal:  Physiol Res       Date:  2005-01-10       Impact factor: 1.881

6.  Apolipoprotein E epsilon4 allele, AD pathology, and the clinical expression of Alzheimer's disease.

Authors:  D A Bennett; R S Wilson; J A Schneider; D A Evans; N T Aggarwal; S E Arnold; E J Cochran; E Berry-Kravis; J L Bienias
Journal:  Neurology       Date:  2003-01-28       Impact factor: 9.910

7.  Studies of familial type III hyperlipoproteinemia using as a genetic marker the apoE phenotype E2/2.

Authors:  J L Breslow; V I Zannis; T R SanGiacomo; J L Third; T Tracy; C J Glueck
Journal:  J Lipid Res       Date:  1982-11       Impact factor: 5.922

8.  Common and rare genotypes of human apolipoprotein E determined by specific restriction profiles of polymerase chain reaction-amplified DNA.

Authors:  P Richard; G Thomas; M P de Zulueta; J L De Gennes; M Thomas; A Cassaigne; G Béréziat; A Iron
Journal:  Clin Chem       Date:  1994-01       Impact factor: 8.327

Review 9.  Genetic heterogeneity of apolipoprotein E and its influence on plasma lipid and lipoprotein levels.

Authors:  P de Knijff; A M van den Maagdenberg; R R Frants; L M Havekes
Journal:  Hum Mutat       Date:  1994       Impact factor: 4.878

10.  Increased frequencies of apolipoprotein epsilon 2 and epsilon 4 alleles in patients with ischemic heart disease.

Authors:  M Eto; K Watanabe; I Makino
Journal:  Clin Genet       Date:  1989-09       Impact factor: 4.438

View more
  1 in total

1.  Challenges at the APOE locus: a robust quality control approach for accurate APOE genotyping.

Authors:  Michael E Belloy; Sarah J Eger; Yann Le Guen; Vincent Damotte; Shahzad Ahmad; M Arfan Ikram; Alfredo Ramirez; Anthoula C Tsolaki; Giacomina Rossi; Iris E Jansen; Itziar de Rojas; Kayenat Parveen; Kristel Sleegers; Martin Ingelsson; Mikko Hiltunen; Najaf Amin; Ole Andreassen; Pascual Sánchez-Juan; Patrick Kehoe; Philippe Amouyel; Rebecca Sims; Ruth Frikke-Schmidt; Wiesje M van der Flier; Jean-Charles Lambert; Zihuai He; Summer S Han; Valerio Napolioni; Michael D Greicius
Journal:  Alzheimers Res Ther       Date:  2022-02-04       Impact factor: 6.982

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.